These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 32970217

  • 1. Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases.
    Malarte ML, Nordberg A, Lemoine L.
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1093-1102. PubMed ID: 32970217
    [Abstract] [Full Text] [Related]

  • 2. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
    Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A.
    Alzheimers Res Ther; 2017 Dec 11; 9(1):96. PubMed ID: 29229003
    [Abstract] [Full Text] [Related]

  • 3. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.
    Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, Lott I, Carroll S, Bharani K, Thomas S, Gilmore A, Hamlett ED, Nordberg A, Granholm AC.
    Mol Neurodegener; 2020 Nov 23; 15(1):68. PubMed ID: 33222700
    [Abstract] [Full Text] [Related]

  • 4. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
    Malarte ML, Gillberg PG, Kumar A, Bogdanovic N, Lemoine L, Nordberg A.
    Mol Psychiatry; 2023 Mar 23; 28(3):1272-1283. PubMed ID: 36447011
    [Abstract] [Full Text] [Related]

  • 5. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
    Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y.
    J Nucl Med; 2016 Feb 23; 57(2):208-14. PubMed ID: 26541774
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.
    Mohammadi Z, Alizadeh H, Marton J, Cumming P.
    Biomolecules; 2023 Feb 03; 13(2):. PubMed ID: 36830659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.
    Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, Lashley T, Sander K.
    Brain; 2021 Sep 04; 144(8):2284-2290. PubMed ID: 33742656
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies.
    Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, Berndt M, Schmitt-Willich H, Darmency V, Gabellieri E, Boudou C, Juergens T, Varisco Y, Vokali E, Hickman DT, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A.
    Eur J Nucl Med Mol Imaging; 2019 Sep 04; 46(10):2178-2189. PubMed ID: 31264169
    [Abstract] [Full Text] [Related]

  • 14. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
    Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, Mercier J, Hannestad J, Gillard M.
    Mov Disord; 2018 Feb 04; 33(2):273-281. PubMed ID: 29278274
    [Abstract] [Full Text] [Related]

  • 15. MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer's Disease Model Mice.
    Kang S, Kim J, Lee SY, Okamura N, Chang KA.
    Int J Mol Sci; 2022 May 14; 23(10):. PubMed ID: 35628296
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site.
    Tago T, Toyohara J, Harada R, Furumoto S, Okamura N, Kudo Y, Takahashi-Fujigasaki J, Murayama S, Ishii K.
    Ann Nucl Med; 2019 Jun 14; 33(6):375-382. PubMed ID: 30796626
    [Abstract] [Full Text] [Related]

  • 17. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case.
    Marquié M, Verwer EE, Meltzer AC, Kim SJW, Agüero C, Gonzalez J, Makaretz SJ, Siao Tick Chong M, Ramanan P, Amaral AC, Normandin MD, Vanderburg CR, Gomperts SN, Johnson KA, Frosch MP, Gómez-Isla T.
    Acta Neuropathol Commun; 2017 Oct 19; 5(1):75. PubMed ID: 29047416
    [Abstract] [Full Text] [Related]

  • 18. Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography.
    Lemoine L, Saint-Aubert L, Nennesmo I, Gillberg PG, Nordberg A.
    Sci Rep; 2017 Apr 04; 7():45496. PubMed ID: 28374768
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects.
    Guehl NJ, Wooten DW, Yokell DL, Moon SH, Dhaynaut M, Katz S, Moody KA, Gharagouzloo C, Kas A, Johnson KA, El Fakhri G, Normandin MD.
    Eur J Nucl Med Mol Imaging; 2019 Sep 04; 46(10):2099-2111. PubMed ID: 31332496
    [Abstract] [Full Text] [Related]

  • 20. Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.
    Cai L, Qu B, Hurtle BT, Dadiboyena S, Diaz-Arrastia R, Pike VW.
    ACS Chem Neurosci; 2016 Jul 20; 7(7):897-911. PubMed ID: 27171905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.